MedDataX Logo

Social-software iMproving wARfarin Therapy

NCT03264937 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 735

Last updated 2019-06-19

No results posted yet for this study

Summary

Poor anticoagulation quality is a major problem among Chinese patients receiving warfarin therapy in traditional health care settings. Improving warfarin therapy has been crucial for Chinese patients. Wechat is social-software in China. Most of all Chinese adults use Wechat, as well as our patients. So we set up a Wechat-based mini-program to instruct Chinese patients' warfarin therapy. We aim to assess whether social software could improve warfarin therapy in Chinese patients by conducting a single-centre, open-label, prospective, randomized clinical trial.

Conditions

  • Anticoagulants Causing Adverse Effects in Therapeutic Use
  • Patient Compliance

Interventions

BEHAVIORAL

Social-software management

Using Wechat application, a social platform, to manage warfarin therapy in patients with mechanical valve replacement.

Sponsors & Collaborators

  • Wuhan Asia Heart Hospital

    lead OTHER

Principal Investigators

  • Zhenlu Zhang, MD,PhD · Wuhan Asia Heart Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2019-03-01
Completion
2019-03-08

Countries

  • China

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03264937 on ClinicalTrials.gov